



COMPANY OVERVIEW

Pacific Biosciences offers the PacBio® RS II Sequencing System to help scientists solve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT®) technology, our products enable: *de novo* genome assembly to finish genomes in order to fully identify, annotate and decipher genomic structures; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Our technology provides the industry's highest consensus accuracy and longest read lengths along with the ability to detect real-time kinetic information. The PacBio RS II System, including consumables and software, provides a simple, fast, end-to-end workflow for SMRT Sequencing.

Our customers and our scientific collaborators have published a number of peer-reviewed articles in journals including *Nature*, *Genome Research* and *The New England Journal of Medicine* highlighting the power and applications of the SMRT platform in projects such as finishing genomes, rare mutation discovery and the identification of chemical modifications of DNA related to virulence and pathogenicity. Our R&D efforts are focused on expanding the performance of our platform by exploiting the unique capabilities of our Zero-Mode Waveguide (ZMW)-based technology and by expanding the application space.

By providing access to genetic information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

KEY FACTS

Year Founded: 2000

Number of Employees: 325

Headquarters: Menlo Park, CA

NASDAQ: PACB

Executive Management Team

Michael Hunkapiller, Ph.D., President & Chief Executive Officer

Susan Barnes, Chief Financial Officer

Jonas Korlach, Ph.D., Chief Scientific Officer

Stephen Turner, Ph.D., Founder & Chief Technology Officer

Kevin Corcoran, Sr. Vice President, Market Development

Michael Phillips, Sr. Vice President, Research & Development

Board of Directors

Michael Hunkapiller, Ph.D., President & Chief Executive Officer (Chairman)

David Botstein, Ph.D., Lewis-Sigler Institute Director & Professor, Princeton University

Brook Byers, Partner, Kleiner Perkins Caufield & Byers

Bill Ericson, Partner, Mohr Davidow Ventures

Randy Livingston, Chief Financial Officer, Stanford University

John Milligan, Ph.D., President & Chief Operating Officer, Gilead Sciences

Marshall Mohr, Senior Vice President & CFO, Intuitive Surgical, Inc.

Lucy Shapiro, Ph.D., Professor, Stanford University School of Medicine

Last updated August 19, 2013